Sign up to our newsletter Subscribe
The Importance of Diversity of Supply in Rare Diseases Markets

Sign up to our newsletter Subscribe
The curative nature of cell and gene therapies has the potential to transform our entire approach to healthcare. Approvals have so far been in niche indications but the successful application of similar technologies in broader indications is expected to follow.
As the list of approvals grows, so too does the pressure on payers. The record-breaking price tags for these innovative therapies reflect the savings in medical costs over time, but the sizable upfront costs could create significant challenges for the reimbursement system.
The UK’s Office of Health Economics (OHE) has conducted extensive research into tackling the unique challenges that cell and gene therapies create for industry, regulators, and payors. This event provided an opportunity to hear from our experts on:
An error has occurred, please try again later.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!